The global Competent Cells market size was valued at US$ 2451 million in 2024 and is forecast to a readjusted size of USD 4530 million by 2031 with a CAGR of 9.3% during review period.
Competent cells are bacteria which can accept extra-chromosomal DNA or plasmids. Cells can be made competent in several ways. One such way is to "shock" it, which involves cooling the bacteria in a Calcium Chloride bath at 0 degrees Celsius, then quickly heating it to around 47 degrees Celsius for approximately 90 seconds (too long will denature the cell membrane, killing the bacteria). The calcium chloride ions neutralize the repulsion between the negatively charged phospholipid heads of the cell membrane and the negatively charged phosphate groups on the DNA. The quick heat shock creates a thermal gradient which, in turn, creates a draft leading into the cell, allowing extra-chromosomal DNA (such as plasmids) to enter the cell, allowing the bacterium to be genetically modifed.
Global Competent Cells key players include Beijing TransGen Biotech, Merck KGaA, Thermo Fisher Scientific, Agilent Technologies, etc. Global top four manufacturers hold a share nearly 30%.
North America is the largest market, with a share about 10%, followed by Asia-Pacific and Europe, both have a share about 20 percent.
In terms of product, Chemically Competent Cells is the largest segment, with a share nearly 65%. And in terms of application, the largest application is Protein Expression, followed by Subcloning & Routine Cloning, Phage Display Library Construction, Toxic/Unstable DNA Cloning, etc.
This report is a detailed and comprehensive analysis for global Competent Cells market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Competent Cells market size and forecasts, in consumption value ($ Million), 2020-2031
Global Competent Cells market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Competent Cells market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Competent Cells market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Competent Cells
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Competent Cells market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck KGaA, Thermo Fisher Scientific, Agilent Technologies, Takara Bio, Promega Corporation, Beijing TransGen Biotech, GeneScript Corporation, Yeastern Biotech, New England Biolabs, QIAGEN N.V., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Competent Cells market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Chemically Competent Cells
Electrocompetent Cells
麻豆原创 segment by Application
Subcloning & Routine Cloning
Phage Display Library Construction
Toxic/Unstable DNA Cloning
High-Throughput Cloning
Protein Expression
Mutagenesis
Single-Stranded DNA Production
Bacmid Creation
Cre-Lox Recombination (PIR1/PIR2)
麻豆原创 segment by players, this report covers
Merck KGaA
Thermo Fisher Scientific
Agilent Technologies
Takara Bio
Promega Corporation
Beijing TransGen Biotech
GeneScript Corporation
Yeastern Biotech
New England Biolabs
QIAGEN N.V.
OriGene Technologies
Lucigen
Zymo Research
Bio-Rad Laboratories
Bioline
Delphi Genetics
IBA GmBH
Cell Applications
BioDynamics Laboratory
Scarab Genomics
GCC Biotech
SMOBIO Technology
Edge BioSystems
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Competent Cells product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Competent Cells, with revenue, gross margin, and global market share of Competent Cells from 2020 to 2025.
Chapter 3, the Competent Cells competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Competent Cells market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Competent Cells.
Chapter 13, to describe Competent Cells research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Competent Cells by Type
1.3.1 Overview: Global Competent Cells 麻豆原创 Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Competent Cells Consumption Value 麻豆原创 Share by Type in 2024
1.3.3 Chemically Competent Cells
1.3.4 Electrocompetent Cells
1.4 Global Competent Cells 麻豆原创 by Application
1.4.1 Overview: Global Competent Cells 麻豆原创 Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Subcloning & Routine Cloning
1.4.3 Phage Display Library Construction
1.4.4 Toxic/Unstable DNA Cloning
1.4.5 High-Throughput Cloning
1.4.6 Protein Expression
1.4.7 Mutagenesis
1.4.8 Single-Stranded DNA Production
1.4.9 Bacmid Creation
1.4.10 Cre-Lox Recombination (PIR1/PIR2)
1.5 Global Competent Cells 麻豆原创 Size & Forecast
1.6 Global Competent Cells 麻豆原创 Size and Forecast by Region
1.6.1 Global Competent Cells 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Competent Cells 麻豆原创 Size by Region, (2020-2031)
1.6.3 North America Competent Cells 麻豆原创 Size and Prospect (2020-2031)
1.6.4 Europe Competent Cells 麻豆原创 Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Competent Cells 麻豆原创 Size and Prospect (2020-2031)
1.6.6 South America Competent Cells 麻豆原创 Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Competent Cells 麻豆原创 Size and Prospect (2020-2031)
2 Company Profiles
2.1 Merck KGaA
2.1.1 Merck KGaA Details
2.1.2 Merck KGaA Major Business
2.1.3 Merck KGaA Competent Cells Product and Solutions
2.1.4 Merck KGaA Competent Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Merck KGaA Recent Developments and Future Plans
2.2 Thermo Fisher Scientific
2.2.1 Thermo Fisher Scientific Details
2.2.2 Thermo Fisher Scientific Major Business
2.2.3 Thermo Fisher Scientific Competent Cells Product and Solutions
2.2.4 Thermo Fisher Scientific Competent Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Thermo Fisher Scientific Recent Developments and Future Plans
2.3 Agilent Technologies
2.3.1 Agilent Technologies Details
2.3.2 Agilent Technologies Major Business
2.3.3 Agilent Technologies Competent Cells Product and Solutions
2.3.4 Agilent Technologies Competent Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Agilent Technologies Recent Developments and Future Plans
2.4 Takara Bio
2.4.1 Takara Bio Details
2.4.2 Takara Bio Major Business
2.4.3 Takara Bio Competent Cells Product and Solutions
2.4.4 Takara Bio Competent Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Takara Bio Recent Developments and Future Plans
2.5 Promega Corporation
2.5.1 Promega Corporation Details
2.5.2 Promega Corporation Major Business
2.5.3 Promega Corporation Competent Cells Product and Solutions
2.5.4 Promega Corporation Competent Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Promega Corporation Recent Developments and Future Plans
2.6 Beijing TransGen Biotech
2.6.1 Beijing TransGen Biotech Details
2.6.2 Beijing TransGen Biotech Major Business
2.6.3 Beijing TransGen Biotech Competent Cells Product and Solutions
2.6.4 Beijing TransGen Biotech Competent Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Beijing TransGen Biotech Recent Developments and Future Plans
2.7 GeneScript Corporation
2.7.1 GeneScript Corporation Details
2.7.2 GeneScript Corporation Major Business
2.7.3 GeneScript Corporation Competent Cells Product and Solutions
2.7.4 GeneScript Corporation Competent Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 GeneScript Corporation Recent Developments and Future Plans
2.8 Yeastern Biotech
2.8.1 Yeastern Biotech Details
2.8.2 Yeastern Biotech Major Business
2.8.3 Yeastern Biotech Competent Cells Product and Solutions
2.8.4 Yeastern Biotech Competent Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Yeastern Biotech Recent Developments and Future Plans
2.9 New England Biolabs
2.9.1 New England Biolabs Details
2.9.2 New England Biolabs Major Business
2.9.3 New England Biolabs Competent Cells Product and Solutions
2.9.4 New England Biolabs Competent Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 New England Biolabs Recent Developments and Future Plans
2.10 QIAGEN N.V.
2.10.1 QIAGEN N.V. Details
2.10.2 QIAGEN N.V. Major Business
2.10.3 QIAGEN N.V. Competent Cells Product and Solutions
2.10.4 QIAGEN N.V. Competent Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 QIAGEN N.V. Recent Developments and Future Plans
2.11 OriGene Technologies
2.11.1 OriGene Technologies Details
2.11.2 OriGene Technologies Major Business
2.11.3 OriGene Technologies Competent Cells Product and Solutions
2.11.4 OriGene Technologies Competent Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 OriGene Technologies Recent Developments and Future Plans
2.12 Lucigen
2.12.1 Lucigen Details
2.12.2 Lucigen Major Business
2.12.3 Lucigen Competent Cells Product and Solutions
2.12.4 Lucigen Competent Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.12.5 Lucigen Recent Developments and Future Plans
2.13 Zymo Research
2.13.1 Zymo Research Details
2.13.2 Zymo Research Major Business
2.13.3 Zymo Research Competent Cells Product and Solutions
2.13.4 Zymo Research Competent Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.13.5 Zymo Research Recent Developments and Future Plans
2.14 Bio-Rad Laboratories
2.14.1 Bio-Rad Laboratories Details
2.14.2 Bio-Rad Laboratories Major Business
2.14.3 Bio-Rad Laboratories Competent Cells Product and Solutions
2.14.4 Bio-Rad Laboratories Competent Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.14.5 Bio-Rad Laboratories Recent Developments and Future Plans
2.15 Bioline
2.15.1 Bioline Details
2.15.2 Bioline Major Business
2.15.3 Bioline Competent Cells Product and Solutions
2.15.4 Bioline Competent Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.15.5 Bioline Recent Developments and Future Plans
2.16 Delphi Genetics
2.16.1 Delphi Genetics Details
2.16.2 Delphi Genetics Major Business
2.16.3 Delphi Genetics Competent Cells Product and Solutions
2.16.4 Delphi Genetics Competent Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.16.5 Delphi Genetics Recent Developments and Future Plans
2.17 IBA GmBH
2.17.1 IBA GmBH Details
2.17.2 IBA GmBH Major Business
2.17.3 IBA GmBH Competent Cells Product and Solutions
2.17.4 IBA GmBH Competent Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.17.5 IBA GmBH Recent Developments and Future Plans
2.18 Cell Applications
2.18.1 Cell Applications Details
2.18.2 Cell Applications Major Business
2.18.3 Cell Applications Competent Cells Product and Solutions
2.18.4 Cell Applications Competent Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.18.5 Cell Applications Recent Developments and Future Plans
2.19 BioDynamics Laboratory
2.19.1 BioDynamics Laboratory Details
2.19.2 BioDynamics Laboratory Major Business
2.19.3 BioDynamics Laboratory Competent Cells Product and Solutions
2.19.4 BioDynamics Laboratory Competent Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.19.5 BioDynamics Laboratory Recent Developments and Future Plans
2.20 Scarab Genomics
2.20.1 Scarab Genomics Details
2.20.2 Scarab Genomics Major Business
2.20.3 Scarab Genomics Competent Cells Product and Solutions
2.20.4 Scarab Genomics Competent Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.20.5 Scarab Genomics Recent Developments and Future Plans
2.21 GCC Biotech
2.21.1 GCC Biotech Details
2.21.2 GCC Biotech Major Business
2.21.3 GCC Biotech Competent Cells Product and Solutions
2.21.4 GCC Biotech Competent Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.21.5 GCC Biotech Recent Developments and Future Plans
2.22 SMOBIO Technology
2.22.1 SMOBIO Technology Details
2.22.2 SMOBIO Technology Major Business
2.22.3 SMOBIO Technology Competent Cells Product and Solutions
2.22.4 SMOBIO Technology Competent Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.22.5 SMOBIO Technology Recent Developments and Future Plans
2.23 Edge BioSystems
2.23.1 Edge BioSystems Details
2.23.2 Edge BioSystems Major Business
2.23.3 Edge BioSystems Competent Cells Product and Solutions
2.23.4 Edge BioSystems Competent Cells Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.23.5 Edge BioSystems Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Competent Cells Revenue and Share by Players (2020-2025)
3.2 麻豆原创 Share Analysis (2024)
3.2.1 麻豆原创 Share of Competent Cells by Company Revenue
3.2.2 Top 3 Competent Cells Players 麻豆原创 Share in 2024
3.2.3 Top 6 Competent Cells Players 麻豆原创 Share in 2024
3.3 Competent Cells 麻豆原创: Overall Company Footprint Analysis
3.3.1 Competent Cells 麻豆原创: Region Footprint
3.3.2 Competent Cells 麻豆原创: Company Product Type Footprint
3.3.3 Competent Cells 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Competent Cells Consumption Value and 麻豆原创 Share by Type (2020-2025)
4.2 Global Competent Cells 麻豆原创 Forecast by Type (2026-2031)
5 麻豆原创 Size Segment by Application
5.1 Global Competent Cells Consumption Value 麻豆原创 Share by Application (2020-2025)
5.2 Global Competent Cells 麻豆原创 Forecast by Application (2026-2031)
6 North America
6.1 North America Competent Cells Consumption Value by Type (2020-2031)
6.2 North America Competent Cells 麻豆原创 Size by Application (2020-2031)
6.3 North America Competent Cells 麻豆原创 Size by Country
6.3.1 North America Competent Cells Consumption Value by Country (2020-2031)
6.3.2 United States Competent Cells 麻豆原创 Size and Forecast (2020-2031)
6.3.3 Canada Competent Cells 麻豆原创 Size and Forecast (2020-2031)
6.3.4 Mexico Competent Cells 麻豆原创 Size and Forecast (2020-2031)
7 Europe
7.1 Europe Competent Cells Consumption Value by Type (2020-2031)
7.2 Europe Competent Cells Consumption Value by Application (2020-2031)
7.3 Europe Competent Cells 麻豆原创 Size by Country
7.3.1 Europe Competent Cells Consumption Value by Country (2020-2031)
7.3.2 Germany Competent Cells 麻豆原创 Size and Forecast (2020-2031)
7.3.3 France Competent Cells 麻豆原创 Size and Forecast (2020-2031)
7.3.4 United Kingdom Competent Cells 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Russia Competent Cells 麻豆原创 Size and Forecast (2020-2031)
7.3.6 Italy Competent Cells 麻豆原创 Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Competent Cells Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Competent Cells Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Competent Cells 麻豆原创 Size by Region
8.3.1 Asia-Pacific Competent Cells Consumption Value by Region (2020-2031)
8.3.2 China Competent Cells 麻豆原创 Size and Forecast (2020-2031)
8.3.3 Japan Competent Cells 麻豆原创 Size and Forecast (2020-2031)
8.3.4 South Korea Competent Cells 麻豆原创 Size and Forecast (2020-2031)
8.3.5 India Competent Cells 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Southeast Asia Competent Cells 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Australia Competent Cells 麻豆原创 Size and Forecast (2020-2031)
9 South America
9.1 South America Competent Cells Consumption Value by Type (2020-2031)
9.2 South America Competent Cells Consumption Value by Application (2020-2031)
9.3 South America Competent Cells 麻豆原创 Size by Country
9.3.1 South America Competent Cells Consumption Value by Country (2020-2031)
9.3.2 Brazil Competent Cells 麻豆原创 Size and Forecast (2020-2031)
9.3.3 Argentina Competent Cells 麻豆原创 Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Competent Cells Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Competent Cells Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Competent Cells 麻豆原创 Size by Country
10.3.1 Middle East & Africa Competent Cells Consumption Value by Country (2020-2031)
10.3.2 Turkey Competent Cells 麻豆原创 Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Competent Cells 麻豆原创 Size and Forecast (2020-2031)
10.3.4 UAE Competent Cells 麻豆原创 Size and Forecast (2020-2031)
11 麻豆原创 Dynamics
11.1 Competent Cells 麻豆原创 Drivers
11.2 Competent Cells 麻豆原创 Restraints
11.3 Competent Cells Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Competent Cells Industry Chain
12.2 Competent Cells Upstream Analysis
12.3 Competent Cells Midstream Analysis
12.4 Competent Cells Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Merck KGaA
Thermo Fisher Scientific
Agilent Technologies
Takara Bio
Promega Corporation
Beijing TransGen Biotech
GeneScript Corporation
Yeastern Biotech
New England Biolabs
QIAGEN N.V.
OriGene Technologies
Lucigen
Zymo Research
Bio-Rad Laboratories
Bioline
Delphi Genetics
IBA GmBH
Cell Applications
BioDynamics Laboratory
Scarab Genomics
GCC Biotech
SMOBIO Technology
Edge BioSystems
听
听
*If Applicable.
